Evidence-based management of dyslipidemias in women

Current Atherosclerosis Reports

Volumn 5, Issue 5, 2003, Pages 379-385

  LaRosa, John C ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CYANOCOBALAMIN; DESOGESTREL; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NORETHISTERONE; NORGESTREL; PRAVASTATIN; PYRIDOXINE; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG;

ATHEROSCLEROSIS; BREAST CANCER; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GENDER; HORMONE SUBSTITUTION; HUMAN; KINESIOTHERAPY; LIVER DYSFUNCTION; MAXIMUM PERMISSIBLE DOSE; MYOPATHY; PREDICTION; QUALITATIVE ANALYSIS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 3142619511     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0009-y     Document Type: Review

References (46)

1. Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209-2016.
2. LaRosa JC: Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997, 157:961-968.
3. LaRosa JC, He J, Vupputuri S: Effects of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
4. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
5. Sandkamp M, Assmann G: Lipoprotein(a) in PRO-CAM participants and young myocardial infarction survivors. In Lipoprotein(a). Edited by Scanu AM. New York: Academic Press; 1990:205-209.
6. Brewer HB: Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In Lipoprotein(a). Edited by Scanu AM. New York: Academic Press; 1990: 211-220.
7. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease - application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
8. Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al.: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001, 85:619-625.
9. Tan KC, Chow WS, Tam SC, et al.: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasolidation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563-568.
10. Plenge JK, Hernandez TL, Weil KM, et al.: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
11. Walsh BW, Paul S, Wild RA, et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metal 2000, 85:214-218.
12. Schnyder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593-1600.
13. LaRosa JC: Future clinical trials of lipid-lowering drugs. In Lipids and Atherosclerosis Annual. Edited by Gaw A, Shepherd J. In press.
14. Krolewski AS, Warram JH, Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90:56S-61S.
15. Soler JT, Folsom AR, Kushi LH, et al.: Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins A-1 and B in postmenopausal women. J Clin Epidemiol 1988, 41:1075-1081.
16. Lapidus L, Bengtsson C, Larsson B, et al.: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984, 289:1257-1261.
17. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973, 36:207-214.
18. Barnard RJ: Effects of life-style modification on serum lipids. Arch Intern Med 1991, 151:1389-1394.
19. Bush TL: The epidemiology of cardiovascular disease in post-menopausal women. Ann NY Acad Sci 1990, 592:263-271.
20. van der Schouw YT, van der Graaf Y, Steyerberg EW, et al.: Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996, 347:714-718.
21. The PEPI Investigators: Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208.
22. Adams MR, Register TC, Golden DL, et al.: Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Aterioscler Thromb Vasc Biol 1997, 17:217-221.
23. Psaty BM, Heckbert SR, Atkins D, et al.: The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994, 154:1333-1339.
24. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613.
25. Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522-529.
26. Clarke S, Kelleher J, Lloyd-Jones H, et al.: Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women [abstract]. Eur Heart J 2000, 21:212.
27. Angerer P, Stork S, Kothny W, et al.: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001, 21:262-268.
28. Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243-1249.
29. Hodis HN, Mack WJ, Lobo RA, et al., for the Estrogen in the Prevention of Atherosclerosis Trial Research Group: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135:939-953.
30. deKleijn MJ, Bots ML, Bak AA, et al.: Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Atherosclerosis 1999, 32:195-204.
31. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288:321-333.
32. The ESPRIT Team: Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002, 360:2001-2008.
33. Wood D, De Backer G, Faergeman O, et al.: Prevention of coronary heart disease in clinical practice. Eur Heart J 1998, 19:1434-1503.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
35. Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001, 285:1585-1591.
36. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21-27.
37. Mensink RP, Katan MB: Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987, 8525:122-125.
38. Masarei JR, Rouse IL, Lynch WJ, et al.: Effects of a lacto-ovo vegetarian diet on serum concentration of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am J Clin Nutr 1984, 40:468-478.
39. Ernst N, Bowen P, Fisher M, et al.: Changes in plasma lipids and lipoproteins after a modified fat diet. Lancet 1980, 1:111-113.
40. Lokey EA, Tran ZV: Effects of exercise training on serum lipid and lipoprotein concentrations in women: A meta-analysis. Int J Sports Med 1989, 10:424-429.
41. Hartung GH, Moore CE, Mitchell R, et al.: Relationship of menopausal status and exercise level to HDL cholesterol in women. Exp Aging Res 1984, 10:13-18.
42. Tanko LB, Bagger YZ, Alexandersen P, et al.: Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003, 107:1626-1631.
43. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
44. Sudhop T, Lutjohann D, Kodal A, et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
45. Gagne C, Gaudet D, Bruckert E, for the Ezetimibe Study Group: Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475.
46. Herrington DM, Klein KP: Randomized clinical trials of hormone replacement therapy for treatment or prevention of cardiovascular disease: a review of the findings. Atherosclerosis 2003, 166:203-212.